The three biggest challenges in lung cancer, and how researchers are tackling them

Despite new paradigm-shifting treatments, lung cancer remains a deadly disease – and improving outcomes requires more than just drug research.

The new Lung Ambition Alliance – launched in July last year – has identified three major challengers that are inhibiting long-term survival worldwide: late diagnosis, few treatment advances for early-stage cancer, and disparity in cancer care both worldwide and within countries.